AQR Capital Management LLC Acquires New Shares in Grifols, S.A. (NASDAQ:GRFS)

AQR Capital Management LLC acquired a new stake in Grifols, S.A. (NASDAQ:GRFS) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 14,107 shares of the biotechnology company’s stock, valued at approximately $89,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Cohen Investment Advisors LLC bought a new position in shares of Grifols during the 1st quarter valued at $80,000. Cetera Advisors LLC bought a new position in shares of Grifols during the 1st quarter valued at $147,000. Farallon Capital Management LLC bought a new position in shares of Grifols during the 1st quarter valued at $187,000. Team Hewins LLC lifted its holdings in shares of Grifols by 11.8% during the 1st quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 4,324 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of Grifols during the 1st quarter valued at $316,000.

Grifols Price Performance

NASDAQ GRFS opened at $8.65 on Friday. The business’s fifty day moving average price is $8.58 and its 200-day moving average price is $7.67. The stock has a market capitalization of $5.95 billion, a price-to-earnings ratio of 8.48 and a beta of 0.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15.

Grifols (NASDAQ:GRFS) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion during the quarter. On average, equities analysts predict that Grifols, S.A. will post 0.79 earnings per share for the current year.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.